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Alzheimer’s disease (AD) due to amyloid-b (Ab) neuro-
pathology has become the most pressing health concern in
aging populations, and there are currently no effective treat-
ments available to reduce cognitive decline related to AD
neuropathology. Drugs directed at reducing amyloid load
or increasing Ab clearance, including intervening at down-
stream targets using anti-amyloid antibodies and more up-
stream using BACE inhibition, have been proposed as the
most rational approach to affect the course of AD, but their
failure in recent clinical trials has been disappointing. It is
now believed that treatments targeting amyloid may only
be effective during the extended preclinical or prodromal
phase of AD, driven by knowledge that the disease is typi-
cally associated with a prolonged presymptomatic period
[1]. The current view is therefore that intervention during
the early stages of the pathological process is the way for-
ward, but such trials may be problematic in sporadic AD
(sAD), given the difficulty to identify individuals most at
risk of further decline. Though solutions are being put in
place, these are substantial and resource-intensive initiatives
[2]. There has therefore been increasing interest in trials of
amyloid-targeting drugs in populations with rare genetic
forms of AD, particularly autosomal-dominant AD
(ADAD) due to fully penetrant mutations in the known
AD genes amyloid precursor protein (APP), PSEN1, and
PSEN2. So far, two major trials of this type being conducted
in ADAD are the Alzheimer’s Prevention Initiative and the
Dominantly Inherited Alzheimer’s Network-Trials Unit.
The Dominantly Inherited Alzheimer’s Network-Trials
Unit enrolls mutation carriers as well as people at a 50%
risk for ADAD, with nonmutation carriers allocated to the
placebo arm, and all study drugs used to date directly or indi-
rectly targeting Ab as the therapeutic intervention [3].
Similar initiatives for sAD include the EPAD platform [2].
The possibility to conduct primary prevention studies in
those at risk of Alzheimer’s disease is now increasingly be-
ing considered, and both EMA and FDA guidance docu-
ments have been drafted to address the issues related to
conducting such trials [4,5].
The predictable development of AD pathology and high
incidence of dementia in individuals with Down syndrome
(DS; trisomy 21) suggests that this is another population in
which trials in the preclinical or prodromal stage of AD to
prevent or delay decline should be considered. This is espe-
cially so given this is the simplest cause of disease: overpro-
duction of the APP gene. Ironically, individuals with DS are
currently excluded from clinical trials of Ab-targeting drugs,
in part because of their comorbid intellectual impairment
and other comorbidities, but also because until recently there
has been a lack of biomarker data and validated measures ofclinical progression in this population, and concern about
tolerability of procedures. Intervention studies in people
with DS depend upon determining the optimal age for treat-
ments to be given, identifying or developing reliable
outcome measures that are most sensitive to decline, and
discovering biomarkers most closely related to disease pro-
gression.
In this position paper, we summarize recent progress to
understand disease progression in DS at the clinical, neuro-
imaging, and biomarker levels and review the rationale for
trials to prevent or delay AD-related decline in individuals
with DS. We conclude that a collaborative approach is
required to address remaining challenges, and we describe
a European DS platform (Horizon21 Down Syndrome Con-
sortium) that is developing a clinical trials network and
feasible and acceptable protocols for such trials.
1.1. AD pathogenesis in DS
The discovery that adults with DS have neuropathology
identical to individuals with sAD played a key role in the
identification of Ab contained within amyloid (senile) pla-
ques and the subsequent identification of the APP gene on
chromosome 21 [6]. Further evidence that three copies of
APP lead to AD has been provided by familial cases with
small duplications of the chromosome 21 region encoding
APP who also develop early onset of AD [7]. Conversely,
partial trisomy of chromosome 21 not involving APP does
not lead to AD [8]. DS with APP triplication is thus a genet-
ically determined form of AD, similar to the rare autosomal-
dominant forms of AD (ADAD) [9].
An extra copy of APP results in excess Ab production due
to increased APP expression and through proteolytic pro-
cessing. Some of the earliest AD neuropathological studies
noted the exceptionally young age at which cases with DS
may present with AD pathology [10]; it is now accepted
that all older adults with full trisomy 21 have the neuropath-
ological hallmarks of AD, consisting of a progressive build-
up of extracellular Ab plaques and intraneuronal hyperphos-
phorylated tau [11]. Recently, amyloid pathology in individ-
uals with DS has been demonstrated with in vivo amyloid
PET imaging studies [12] and tangle pathology has been
shown with tau PET [13]. Fibrillar deposits of Ab are
increasingly prevalent with aging in DS brain tissue and
correlate with the development of Alzheimer’s dementia
[14]. Similar to sAD and ADAD, postmortem studies imply
that Ab deposits are histopathologically detectable before
PET imaging becomes “positive for amyloid.”
The amyloid cascade hypothesis posits that Ab is the
“toxic agent” responsible for initiating AD pathogenesis
[15], and DS and ADAD both represent uniquely informa-
tive populations for clinical trials because of the almost
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deposition. More specifically, and unlike most ADAD forms
(which are caused by mutations in several genes resulting in
different mechanisms for Ab deposition such as a change in
ratio between Ab1-40 to Ab1-42, or Ab that is more prone to
aggregation), DS is genetically homogenous with a simple
overproduction of Ab as a cause for AD pathology (much
like the ADAD-causative Swedish mutation in APP). Target-
ing this mechanism is further supported by the finding that
an Icelandic mutation that reduces the production of amyloi-
dogenic species via the processing of APP is protective
against AD [16]. DS is therefore a critical population for
clinical trials of antiamyloid drugs to prevent or delay onset
of dementia.1.2. Opportunities for AD trials in DS
At the population level, adults with DS now have signif-
icantly increased life expectancy compared to their peers
50 years ago, and 40% of individuals with DS in Europe
are currently aged 40 years and older [17]. These older indi-
viduals have an ultra-high risk for dementia; recent estimatesFig. 1. Cross-sectional data showing the distribution of age at dementia diagnosis
Down syndrome.suggest a lifetime risk ofw90% [18]. AD is now the major
cause of morbidity and mortality in older adults with DS,
with a mean age of death of 60 years [19].
The prevalence of AD in DS increases from 9% to 23%
between the ages of 35 and 49 years to 55% in those between
50 and 59 years, and 75% and 100% in persons above the age
of 60 years [20,21]. Dementia diagnosis in DS has a
predictable relationship with age [19] (see Fig. 1). The
average age of diagnosis is 55 years, while cognitive decline
may already be observed after age 40 years, up to 15 years
before the typical age of dementia diagnosis (see Fig. 2).
With an incidence of approximately 1 in 650 to 1000 live
births, there is an estimatedw500,000 individuals with DS
in Europe (6.4/10,000), and w206,000 (6.7/10,000) in the
United States [17,22]. In addition to DS being much more
common than ADAD, there is an ethical imperative for
treatment trials that aim to reduce disease burden within
this population. As a consequence of this, individuals with
DS ought to be considered for trials of suitable treatments.
Such trials may also serve as proof-of-concept (PoC) for
other forms of AD, particularly where excess amyloid or
Ab is implicated as central mechanism, including sADin people with DS. Graph based on Sinai et al., 2018 [19]. Abbreviation: DS,
Fig. 2. (A) Cross-sectional data showing the performance (z-score) of adults with DS on object memory test across age, split by APOE status (2/2, 2/3; 3/3; 3/4,
4/4). Data from the London Down Syndrome Consortium (LonDownS), as yet unpublished. (B) Cumulative incidence of mortality, split by APOE status (2/2,
2/3, 2/4; 3/3; 3/4, 4/4). Data from the Rotterdam group, as yet unpublished. Abbreviation: DS, Down syndrome.
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take much longer to complete (and therefore be prohibitively
expensive to undertake), and where amyloid-independent
pathways may mask potential benefit in some individuals.
Because of the universal presence of amyloid neuropa-
thology in all individuals with full trisomy 21 (which isthe cause of DS in more than 95% of cases) from their
30s, all adults with DS over age 35 years can be considered
to be in a preclinical AD state. This presents a unique oppor-
tunity to undertake primary prevention trials (i.e., to avoid or
reduce amyloid overproduction and its subsequent detect-
able brain deposition and downstream pathological
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delaying the onset of dementia after the presence of detect-
able brain amyloid deposition, but in the absence of criteria
fulfilling features).
Despite the role of DS in the discovery of the basic mech-
anisms of AD and the obvious treatment strategy to reduce
amyloid overproduction in individuals with DS, there are
virtually no such trials currently being conducted. This is
in contradiction to the United Nations Convention on the
rights of persons with disabilities which encourages partici-
pation of persons with disabilities in biomedical research
[23]. Furthermore, the United Nations Convention on the
rights of persons with disabilities requires health profes-
sionals to “provide care of the same quality to persons
with disabilities as to others (.)” [23]. Given the current
lack of clinical data to support treatment strategies of AD
in DS, such trials are imperative for clinicians to live up to
the standards set by the UN.1.3. Challenges to conducting AD trials in DS
There are ethical issues similar to those concerning pre-
vention trials in sAD and ADAD populations, including
starting treatments in a healthy population who may not
develop dementia for several years. It is therefore vital to un-
derstand the “preclinical” (i.e., at risk but before develop-
ment of signs and symptoms) and “prodromal” (i.e., above
a threshold on certain biomarkers, with some cognitive
impairment or behavioral changes, but before dementia
diagnosis) stages of AD in DS to better predict when to start
preventive treatment, as well as to provide data for efficient
trial designs. Such data have, until recently, been lacking in
DS; however, over the past 5 years, we have been focusing
on exploiting clinical, cognitive, fluid biomarker, and imag-
ing data from several DS longitudinal cohorts across Europe
to address these gaps in knowledge (see section “The Hori-
zon21 European Down Syndrome Consortium” below),
while the NIH has recently funded two DS AD biomarker
cohorts in the US (Neurodegeneration in Aging Down Syn-
drome and Alzheimer’s Disease in Down Syndrome).
Individuals with DS are a particularly vulnerable population
due to several factors including prevalence of chronic condi-
tions, and the impact of these conditions on long-term func-
tioning, as well as potential for adverse effects associated
with particular treatments. This needs to be carefully consid-
ered before undertaking treatment trials. Furthermore, individ-
uals with DS have premorbid cognitive impairments that may
affect decision-making capacity. Many individuals with DS
will not possess the capacity required to make decisions about
whether to participate in research studies or not. In these cases,
special ethical safeguards should be respected, and caregivers
have a prominent role in helping to make decisions to partici-
pate or not, as well as to support individuals taking part in trials.
These factors need to be considered when selecting potential
targets and procedures and should inform trial design andrecruitment strategies. However, DS research has moved from
focusing predominantly on policy and care issues such as inclu-
sion, to ensuring access to treatment, starting in the 1970s with
surgical interventions for congenital heart disease. Clinical tri-
als of medication treatments for dementia in DS are now both
desirable and feasible, with recent examples including trials
of vitamin E and memantine to prevent decline [24,25].
Finally, given the relatively low prevalence of DS, it is
ethically obligated to pool resources internationally to
enable timely and representative recruitment across coun-
tries. This also requires harmonization of research proced-
ures and protocols.1.4. The Horizon21 European Down Syndrome
Consortium
It is in this context that clinical research groups across Eu-
rope—focused on the clinical, biomarker, and genetic as-
pects of AD in DS—are collaborating in an ongoing effort
to obtain the necessary data, tools, and infrastructure to
enable PoC trials of treatment to delay or prevent AD in
DS. We are leveraging a globally unique critical mass of
several existing AD-DS cohorts (with a combined total of
more than 1000 older participants with DS) to pool our
data and bioresources to address current gaps in knowledge
about AD in DS.
The Horizon21 DS Consortium consists of DS cohorts
from the UK (the London Down Syndrome Consortium
[LonDownS] and the Cambridge Dementia in Down’s Syn-
drome [DiDS] cohort), Netherlands (the Rotterdam Down
syndrome study and the Health Watch study), Germany
(AD21 study group, Munich), France (TriAL21 for Lejeune
Institute, Paris), and Spain (the Down Alzheimer Barcelona
Neuroimaging Initiative (DABNI). We have developed a
consortium model that is focused on delivering essential
data on clinical progression of the early stages of AD in
DS, while developing a clinical trials network. The con-
sortium has as its starting point a DS trial-ready cohort
that builds on existing studies to establish a large multina-
tional cohort of individuals with DS with run-in data, which
will also serve as a registry of potential trial participants.
This is linked with a genomics project already underway,
pooling DNA data to conduct genome-wide association
studies (GWAS) of cognitive decline in DS to understand
the genetic factors underlying variation in age of onset of
disease. Another key initial aim of the consortium is to iden-
tify and refine cognitive outcome measures, alongside
harmonization of assessments and procedures. We are also
working to identify feasible interim markers of disease pro-
gression by exploring the relationship between fluid bio-
markers, neuroimaging, and the development of cognitive
decline in DS [26–30].
In the sections below, we describe progress made and
highlight aspects of future work to establish clinical trials
of treatments to prevent or delay AD in individuals with DS.
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Recruitment to clinical trials is potentially challenging,
but enrollment benefits from access to existing registries of
eligible participants. Furthermore, enrollment will likely
be speeded up if information that is important for participant
selection is already known, such as trisomy status, clinical
diagnosis, and whether the individual already has symptoms
suggestive of AD. Longitudinal assessment is also necessary
to measure change against individual baselines, which over-
comes the complexities related to variable premorbid
expression of cognitive impairments, and has the added
advantage of providing run-in data that have the potential
to reduce sample sizes of trials [2].
Horizon21 is developing a harmonized core assessment
protocol, which will be used to follow our combined cohorts.
Participants will undergo identical protocols for longitudinal
clinical phenotyping. Participants will be asked to consent to
inclusion in a coordinated participant registry, consisting of
regularly updated contact details kept separately from clinical
data, but with anonymized linkage to run-in data. At the most
basic level, run-in variables will include age, apolipoprotein E
(APOE) genotype, clinical diagnoses, cognitive test scores
(particularly premorbid IQ or ability level), as well as infor-
mation on potential exclusion criteria for trials. Participants
will be followed with sequential assessments. Such longitudi-
nal data will allow us to identify clinical markers of progres-
sion in cognitive abilities, using multivariate approaches and
survival analyses to inform trial design. The first recruitment
to a run-in cohort will start toward the end of 2018, with the
first phase being focused on validating cognitive outcome
measures (identified using the methods described below)
and a harmonized assessment protocol, as well as to obtain
baseline genetic and blood biomarker data. Subsequent
waves of recruitment are planned to allow for a dynamic
cohort of individuals within the age ranges suitable for both
prevention and disease-modifying trials (see Fig. 3).1.6. Genetic analyses to refine estimates of age at onset in
DS
Genetic analysis could enable a clearer and more precise
estimate of the age at which amyloid deposition and clinical
dementia begin in DS to prepare for and to power clinical tri-
als. We have pooled all available DNA for the Horizon21 DS
genomics study, which now includes data from more than
1000 individuals with DS. Our data show that the APOE
ε4 allele is an important determinant of clinical age at onset
(see Fig. 2); this can potentially be used in staging models
[31]. Preliminary analyses also suggest that other GWAS
hits such as PICALM may have a role [32]. A current aim
is to investigate whether incorporating other genetic markers
improves predictions of onset age and could thus have value
in sample size calculation for trials. A parsimonious hypoth-
esis would be that GWAS hits for diploid AD will have ef-
fects on age at onset in DS, but one might also expect thatother chromosome 21 loci may play a significant role or
that, because APP expression is clearly a key, genes that
have direct effects on APP processing may have a larger
role in DS than in the general population. In addition,
2%–4% of DS cases are mosaic, and 2%–4% are due to
translocations; these will be investigated to establish if
they follow the general “rules” that apply to the majority
of DS cases and to determine whether they should be
included in PoC trials.1.7. Developing cognitive outcome measures for AD trials
in DS
Trials of AD treatments in DS require reliable clinical
outcome measures. In individuals with DS, the develop-
ment of dementia needs to be understood in the context
of a complex cognitive phenotype that includes not only
variable degrees of intellectual impairment but also specific
(and variable) impairments in executive function, memory,
language, and motor domains [33]. These preexisting im-
pairments need to be distinguished from subsequent
decline and, in combination with varying baseline abilities
and limitations in speech abilities, can complicate the clin-
ical diagnosis of dementia and interpretation of cognitive
test data.
Cognitive tests of domains commonly affected in sAD
have been adapted for use in individuals with DS, and there
are some data to suggest that these can discriminate between
those with and without dementia as well as to track cognitive
decline [33–35]. However, floor effects are a concern, and
approximately a third of older DS participants without
dementia may be unable to perform complex cognitive
tasks, affecting their suitability as clinical trial outcome
measures. Furthermore, some tests are limited by their
reliance on verbal language abilities, which is a particular
issue for individuals with DS. Language-heavy tests also
limit their applicability across multinational and multicul-
tural settings.
In addition, there are no agreed definitions of prodromal
stages of AD in DS when some symptoms may already be
present, but before clinical diagnosis of dementia is possible
(diagnosis is generally made at a relatively late stage in the
process of pathology). Most previous studies of decline in
DS were small scale and results were mixed; some identified
early changes in memory [35], while others suggested
changes in executive function, behavior, and personality
occur before AD diagnosis [36]. Because a common
approach is to use informant questionnaires to obtain
detailed information on the development of behavioral or
cognitive symptoms related to the onset of dementia, it is
possible that some of these findings reflect the changes
that are noticed first by caregivers and thus not necessarily
representative of the underlying sequence of dementia-
associated changes. Informant-rated tools may be more use-
ful in trials targeting later stages of disease when prominent
symptoms are present.
Fig. 3. Flow diagram showing existing DS trial-ready cohorts. Abbreviation: DS, Down syndrome.
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sophisticated neuropsychological tools to track cognitive
decline in this population for use as outcome measures in
clinical trials.
The Horizon21 DS consortium is using existing data from
our ongoing longitudinal studies of AD in DS to identify thecognitive domains affected in the early (prodromal) stages of
AD.We are applying statistical methods such as Least Abso-
lute Shrinkage and Selection Operator (LASSO) regression
[37]. This is an ideal method for variable selection when a
set of predictors may be correlated, as with cognitive tests
or clinical rating scales. It is a data-driven method to identify
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outcome, to identify the tests most related to the outcome
of interest. Potentially, LASSO could be used to identify
cognitive tests that are sensitive to cognitive change. In addi-
tion, we may use an event-based model (EBM), another
data-driven model capable of estimating biomarker order-
ings and staging of participants. The EBM has been applied
previously to imaging, CSF, and cognitive markers in sAD
and to model more complex cognitive data sets in ADAD
[38]. We have recently applied EBM to estimate the order
of cognitive decline of AD in DS and assign participants
to a disease stage, which suggests that tests of memory
and attention are most sensitive to early AD decline [39];
however, it is necessary to confirm this longitudinally and
across cohorts stratified by level of ID.
Within Europe, the CAMCOG-DS [40] is a composite
measure often used in both clinical and research settings
but has some limitations, being fairly long, with several
potentially redundant items and few memory items, as
well as relying on culturally sensitive concepts, pictures,
and language. It has already been translated into several Eu-
ropean languages. Horizon21 is working to improve and
refine the CAMCOG-DS, using existing longitudinal data
and item-level analysis. A revised version of the
CAMCOG-DS will be validated in our longitudinal run-in
cohort.
Finally, as definitions of mild cognitive impairment are
difficult to apply in DS due to premorbid memory deficits
and the potential for impoverished subjective reporting, we
will use data on symptom development (obtained using the
CAMDEX-DS informant questionnaire) from our existing
longitudinal studies to identify symptoms that can be reliably
used to define stages during the prolonged preclinical period
of AD in DS, based on existing models of disease such as
those of the International Working Group [1], or the staging
system proposed in the draft FDA guideline [41], which will
be validated alongside cognitive tests in a run-in cohort.1.8. Patient stratification for clinical trials
Amyloid markers using either CSF biomarkers or amy-
loid PET scans are central in patient stratification. Individ-
uals with DS who are amyloid “negative” will be
candidates for primary prevention trials, in which the pri-
mary objective is likely to be an attenuation in the accumu-
lation of amyloid. Those with “positive” results, but without
AD-related cognitive impairment, would qualify for second-
ary prevention using disease-modifying drugs, in which on
top of Ab removal, other neurodegenerative markers or sen-
sitive cognitive measures could constitute the primary out-
comes. Neuroimaging is becoming an increasingly useful
tool in understanding the pathogenesis of dementia develop-
ment in relation to clinical symptoms and several Horizon21
groups are undertaking ongoing neuroimaging studies to
identify the parameters required for patient stratification.So far, studies in Europe and the United States have
demonstrated that individuals with DS have amyloid-
positive PET scans by the age of 50 [14,42], with a
conversion to amyloid positivity happening during a
relatively narrow age range after 40, thus an opportunity
for primary prevention, as defined using amyloid PET.
Although amyloid load, as measured by PET, may not
correlate well with cognitive function in adults who have
DS in cross-sectional studies, longitudinal studies suggest
a significant relationship [14].
CSF biomarkers, which can be used to contribute to AD
diagnoses in the general population and allow for biomarker
stratification (both for amyloid and tau pathologies, aswell as
neurodegeneration), are another option, but have been less
studied in DS [43]. The safety of lumbar puncture in this pop-
ulation has been proven by members of our consortium [44].1.9. Surrogate markers of efficacy and safety
Neuroimaging and blood biomarkers could be used as
surrogate markers of efficacy. Blood draws are less costly
and more acceptable than brain scans, and blood biomarkers
would be ideal as method of stratification, but identification
of such markers has become the holy grail of AD research.
Recently, several studies have demonstrated that blood con-
centration of neurofilament light (NfL)—a component of
axonal scaffolding proteins that is released after axonal dam-
age—is increased in several neurological disorders associ-
ated with neurodegeneration. This includes both ADAD
and sAD, where increased NfL has been associated with
mild cognitive impairment in addition to cognitive,
biochemical, and imaging hallmarks of AD [45,46].
Members of the Horizon21 consortium have also identi-
fied NfL as a feasible blood biomarker of neurodegeneration
associated with AD in DS [29,47] (Fig. 4), which may offer
an exciting opportunity for tracking response to treatment.
However, it remains to be established how NfL relates to
other biomarkers of disease progression in DS, including
amyloid PET, MRI neuroimaging, and the development of
clinical symptoms. Other biomarkers that have previously
been associated with AD in DS include plasma amyloid
and tau [48], plasma exosomes [28], and markers of oxida-
tive stress and inflammation [26,49,50].
MRI markers of neurodegeneration have been associated
with Ab1 status in DS [51], and thus sequential MRI can be
used to establish the sequence of brain changes concurrent
with, or after conversion to Ab1 on PET scans. The con-
sortium includes several groups that are currently obtaining
longitudinal MRI data for this purpose. In subjects with
negative amyloid PET scans, changes in the rate of change
of amyloid accumulation could be used as a surrogate mea-
sure for amyloid targeting drugs.
Finally, anti-amyloid therapies are associated with
adverse events, including amyloid-related imaging abnor-
malities. These phenomena have also been observed in con-
trols in trials for sAD. We have shown that MRI markers of
Fig. 4. Neurofilament light concentration (ng/L) by age and dementia status of adults with DS. Graph based on Strydom et al., 2018 [29]. Abbreviation: DS,
Down syndrome.
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intensities) are more frequently found in DS than in sporadic
AD [44] but their clinical relevance still needs to be estab-
lished, and we therefore have ongoing longitudinal MRI
studies to establish this.2. Conclusions
Trisomy of chromosome 21, with an extra copy of the
APP gene, has been critically important to understand the
pathophysiology associated with Ab production and deposi-
tion, but despite an ultra-high risk for developing AD, indi-
viduals with DS have yet to be included in clinical trials of
treatments targeting the amyloid mechanism. DS is much
more common than all of the autosomal-dominant causes
of AD combined, and it is thus surprising that such trials
are not considered in this population. The ethical imperative
for treatment trials that aim to reduce the disease burden in
DS remains unfulfilled.
Although there has, until recently, been a lack of
knowledge about in vivo markers of progression of dis-
ease, several studies have demonstrated the similarity inamyloid pathology and neurodegeneration between DS
and most types of ADAD using neuropathological, amy-
loid PET, and MRI neuroimaging studies. Furthermore,
there is a growing literature on blood biomarkers associ-
ated with the development of AD in DS, and pilot data
from Horizon21 study groups on CSF biomarkers suggest
similar associations to age and AD status as those
observed in studies in ADAD populations. Although
some questions about tolerability of procedures remain,
we have demonstrated that many DS individuals, particu-
larly younger individuals in the preclinical stages of AD,
can tolerate procedures such as lumbar punctures, PET,
and MRI imaging and can participate in detailed cognitive
phenotyping studies. We have also made progress in iden-
tifying potential cognitive outcomes that are sensitive to
early decline, and development of reliable cognitive test
measures is well underway. A concerted, collaborative
approach is now required to overcome remaining issues,
provide essential data for trials in DS, and to establish
the infrastructure and networks required to run large-
scale trials. This will require collaboration with clinical
experts, industry, caregivers, and participants to design
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and deliver efficient trial designs.
The Horizon21 project has identified three main areas to
focus on: to create a trial-ready cohort across countries with
run-in data to enable efficient recruitment to trials, which
will also help to establish the necessary infrastructure and
expertise across sites; to develop and validate clinical trial
outcome measures; and to improve on predementia disease
models through the accumulation of clinical and biomarker
data that is necessary to enable trials of treatment to prevent
dementia in DS.
The consortium will engage with key stakeholders,
including patients with DS and cognitive decline, their care-
givers, and other experts and industry partners, to develop
protocols for AD Prevention Trials. These protocols will
be conceptualized to deliver evidence of the impact of an
intervention on a biomarker and/or early cognitive decline
as intermediate phenotype(s) to provide initial evidence of
clinical benefit before being tested in confirmatory trials.
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1. Systematic review and Interpretation: Intervention
during the early stages of the pathological process
of Alzheimer’s disease may hold the key to preven-
tion of clinical progression, but this may be problem-
atic in sporadic Alzheimer’s disease as it is not yet
possible to identify high-risk individuals. There has
therefore been considerable interest in conducting
prevention trials in individuals with genetic forms
of Alzheimer’s disease, where all individuals are at
risk, such as those with autosomal dominant muta-
tions. Individuals with Down syndrome also invari-
ably develop Alzheimer’s disease pathology, but
until recently they have not been the focus of much
research.
2. Future directions: We summarize recent progress in
clinical research on cognitive and biomarker changes
associated with the development of dementia in
Down syndrome to highlight the potential for under-
taking primary and secondary prevention trials in this
population.References
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